SXTC

China SXT Pharmaceuticals, Inc. is a healthcare company operating in the drug manufacturers - specialty & generic industry. The company has a market capitalization of $203.05 million and generates revenue of $1.54 million on an annualized basis. With 75 employees, it operates at a relatively small scale compared to larger pharmaceutical companies. The company's financial health is challenging, with negative profitability metrics across the board. Gross margin stands at 21.7%, while operating margin and profit margin are -1011.7% and 0.0%, respectively. Returns on equity and assets are also negative, at -50.3% and -18.3%, respectively. The balance sheet shows a relatively low level of debt at $1.20 million, which is largely offset by cash reserves of $21.31 million. The company's valuation metrics suggest significant undervaluation or overvaluation, depending on one's perspective. With a price-to-book ratio of 10.06 and price-to-sales ratio of 132.02, the stock may be seen as expensive compared to its peers. The negative EV/EBITDA of -21.95 indicates that investors are willing to pay more for each dollar of EBITDA than the company's actual earnings suggest.